vTv Therapeutics Inc - Asset Resilience Ratio
vTv Therapeutics Inc (VTVT) has an Asset Resilience Ratio of 0.22% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how vTv Therapeutics Inc's Asset Resilience Ratio has changed over time. Check vTv Therapeutics Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down vTv Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see VTVT market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $85.00K | 0.22% |
| Total Liquid Assets | $85.00K | 0.22% |
Asset Resilience Insights
- Limited Liquidity: vTv Therapeutics Inc maintains only 0.22% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
vTv Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare vTv Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for vTv Therapeutics Inc (2013–2024)
The table below shows the annual Asset Resilience Ratio data for vTv Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.22% | $85.00K | $38.27 Million | -0.37pp |
| 2023-12-31 | 0.59% | $65.00K | $11.02 Million | +0.54pp |
| 2022-12-31 | 0.05% | $15.00K | $33.24 Million | -0.35pp |
| 2021-12-31 | 0.39% | $100.00K | $25.47 Million | -2.12pp |
| 2020-12-31 | 2.51% | $371.00K | $14.79 Million | -0.19pp |
| 2019-12-31 | 2.70% | $250.00K | $9.27 Million | -10.43pp |
| 2018-12-31 | 13.13% | $1.12 Million | $8.56 Million | +12.55pp |
| 2017-12-31 | 0.58% | $162.00K | $27.92 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $54.49 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $91.53 Million | -- |
| 2014-12-31 | 1.00% | $130.00K | $12.95 Million | +0.56pp |
| 2013-12-31 | 0.45% | $69.00K | $15.50 Million | -- |
About vTv Therapeutics Inc
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company… Read more